SSD during pregnancy linked to neurodevelopmental delay in boys, with association partly mediated by cord blood C-peptide<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Oct. 3, 2024 (HealthDay News) — Maternal short sleep duration (SSD) during midpregnancy is associated with an increased incidence of neurodevelopmental delay in boys, according to a study published online Sept. 26 in the Journal of Clinical Endocrinology & Metabolism<\/em>.<\/p>\n Lei Zhang, Ph.D., from the School of Public Health at Anhui Medical University in Hefei, China, and colleagues examined the association between SSD in pregnancy and offspring neurodevelopmental delay in a cohort study involving 7,059 mother-child pairs from the Maternal & Infants Health in Hefei cohort. Sleep data during pregnancy were collected at weeks 24 to 28 and 32 to 36. Neurodevelopmental outcomes were assessed from six to 36 months postpartum.<\/p>\n The researchers observed a significant association between mothers with SSD during midpregnancy and neurodevelopmental delay in boys (adjusted hazard ratio, 2.05). In an analysis of cord blood markers, a positive relationship was seen between cord blood serum C-peptide levels and neurodevelopmental delay in offspring (relative risk, 0.04). Cord blood C-peptide mediated 11.05 percent of the association between SSD and neurodevelopmental delay.<\/p>\n “Maternal SSD was positively linked with an increased frequency of neurodevelopmental delay in neonates,” the authors write. “We provide new evidence that cord blood serum C-peptide partly mediates the association of SSD in midpregnancy with neurodevelopmental delay in boys.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n